



SpeedX Awarded REDI Fellowship To Support Next Generation Resistance Guided Therapy For *Mycoplasma genitalium*

*Collaboration with researchers at The University of Queensland aims to improve
detection of antimicrobial resistant STI superbug*

SYDNEY, AUSTRALIA — (May 12, 2022). SpeedX Pty. Ltd., a developer of innovative molecular diagnostic solutions, announced it has been awarded a 12-month Researcher Exchange and Development within Industry initiative Fellowship (REDIF21) sponsoring Postdoctoral Researcher Dr Emma Sweeney from The University of Queensland. With a focus on Resistance Guided Therapy, the fellowship will support the commercialisation of a resistance test to aid in the management of *Mycoplasma genitalium*, a sexually transmitted infection (STI) exhibiting high levels of antibiotic resistance.

The \$32 million REDI Fellowship Program is supported by MTPConnect's Researcher Exchange and Development within Industry (REDI) initiative funded by the Medical Research Future Fund (MRFF). REDI provides industry experience and skills development for researchers, clinicians and other professionals within MTP (medical technology, biotechnology and pharmaceutical) industry and aims to build the skills and capacity to build the rapidly changing MTP sector.

M. genitalium can cause infections such as urethritis, cervicitis, endometritis and pelvic inflammatory disease. In recent studies, it has been found to have a higher prevalence than gonorrhoea. Like gonorrhoea, *M. genitalium* is evolving into a so-called STI superbug that is becoming resistant to many antibiotic treatments, leading to exceedingly difficult-to-treat infections and threatening global public health.

We are able to continue this valuable work through the ongoing support of The ARC ITRP Research Hub to Combat Antimicrobial Resistance (Project ID: IH190100021) in collaboration between the following organisations: Australian universities: UNSW Sydney (Kirby Institute, Centre for Social Research in Health), University of Queensland, Monash University, UTS and University of Melbourne.

About SpeedX

Founded in 2009, SpeedX is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeedX specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeedX please see: <https://plexpcr.com>

References

Contacts

SpeedX

Australia, New Zealand and Europe

Colin Denver - SpeedX

+61 412 733 455

